SWM
VKTX icon

SHP Wealth Management’s Viking Therapeutics VKTX Stock Holding History

SHP Wealth Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$618 Buy
+19
New +$611 ﹤0.01% 1581

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

SHP Wealth Management's VKTX Position: Q1 2026 in Review

SHP Wealth Management opened a new position in Viking Therapeutics (VKTX) in Q1 2026: 19 shares worth $618. The stake represents ﹤0.01% of the portfolio and ranks #1581 among its holdings.

412 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • SHP Wealth Management held 19 shares of Viking Therapeutics worth $618 as of Q1 2026.
  • Viking Therapeutics was a new SHP Wealth Management position in Q1 2026.
  • Viking Therapeutics made up ﹤0.01% of SHP Wealth Management's portfolio in Q1 2026, its #1581 holding.
  • 412 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on SHP Wealth Management's 13F filing for Q1 2026, filed 8 May 2026.